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Abstract: To compare immunonutrition versus standard high calorie
nutrition in patients undergoing elective colorectal resection within an
Enhanced Recovery After Surgery (ERAS) program.
Despite progress in recent years in the surgical management of
patients with colorectal cancer (ERAS programs), postoperative com-
plications are frequent. Nutritional supplements enriched with immu-
nonutrients have recently been introduced into clinical practice.
However, the extent to which the combination of ERAS protocols
and immunonutrition benefits patients undergoing colorectal cancer
surgery is unknown.
The SONVI study is a prospective, multicenter, randomized trial
with 2 parallel treatment groups receiving either the study product (an
immune-enhancing feed) or the control supplement (a hypercaloric
hypernitrogenous supplement) for 7 days before colorectal resection, Francisco Javier PhD,
D, and Antonio Arroyo, MD, PhD
analytical and nutritional parameters. The median length of the post-
operative hospital stay was 5 days with no differences between the
groups. A decrease in the total number of complications was observed in
the immunonutrition group compared with the control group, primarily
due to a significant decrease in infectious complications (23.8% vs.
10.7%, P¼ 0.0007). Of the infectious complications, wound infection
differed significantly between the groups (16.4% vs. 5.7%, P¼ 0.0008).
Other infectious complications were lower in the immunonutrition
group but were not statistically significantly different.
The implementation of ERAS protocols including immunonutrient-
enriched supplements reduces the complications of patients undergoing
colorectal resection.
This study is registered with ClinicalTrial.gov: NCT02393976.
(Medicine 95(21):e3704)
Abbreviations: ASA = American Society of Anesthesiologists
physical status, ERAS = Enhanced Recovery After Surgery, HHS =
hypercaloric, high-protein supplement, IEF = immune-enhancing
feed, LOS = length of stay.
INTRODUCTION
T he introduction of the Enhanced Recovery After Surgery(ERAS) programs in the last decade has led to substantial
improvements in the care of patients undergoing surgery on a
scheduled basis.1,2 Strong evidence, including several clinical
trials and a recent Cochrane Library systematic review, demon-
strates that adherence to ERAS protocols can minimize mor-
bidity while being cost-effective in shortening the length of stay
(LOS) in the hospital following colorectal surgery.3–8 However,
postoperative complications remain common, which affect the
LOS, costs, and income associated with increased mortality.
Infections remain among the major complications that
follow colorectal surgery. It is difficult to anticipate when such
complications occur because their causes are varied. Further-
more, immunosuppression caused by surgical stress is one of the
most important factors in complication development.9
In recent years, standard nutritional formulas have been
modified by the addition of arginine, omega-3 fatty acids,
glutamine, and other components, which may increase immune
responses by modulating inflammatory responses or enhancing
protein synthesis after surgery. The potential effects of these
immunonutrients include reducing infectious and other
postoperative complications.
The aim of this study is to examine whether the joint
munonutrition with an ERAS program
mortality, and LOS compared with
plements. At present, few studies have
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TABLE 1. Composition of Diet
Constituents (per 100 mL) ATEMPERO SUPRESSI
Energy, kcal 151 125
Protein, g, of which 8.3 6.3
Arginine 1
RNA 0.2
Carbohydrate, g, of which 13.3 13.1
Sugars 1 0.4
Fat, g 5 4.9
Omega-3-fatty acids 0.77
Fiber, g 1.7 1.9
Osmolarity, mOsm/L 366 229
Sodium, mg 100 88
Potassium, mg 250 250
Chloride, mg 100 88
Calcium, mg 120 100
Magnesium, mg 31 20
Phosphorus, mg 115 94
Iron, mg 1.7 1.4
Zinc, mg 2.2 1.4
Copper, mg 169 141
Manganese, mg 0.27 0.19
Iodine, mg 18 13
Fluorine, mg 0.21 0.15
Chromium, mg 3.9 2.5
Molybdenum, mg 8.1 5.5
Selenium, mg 7.1 5.9
Vitamin A, mg 200 107
Vitamin D, mg 3.3 3
Vitamin E, mg 4.5 3.1
Vitamin K, mg 7.9 6.5
Vitamin B1, mg 0.33 0.28
Vitamin B2, mg 0.33 0.28
Niacin, mg 2.2 1.8
Vitamin B6, mg 0.33 0.28
Vitamin B12, mg 1 0.4
Pantothenic acid, mg 1.2 1
Biotin, mg 6 5
Folic acid, mg 41 40
Medicine  Volume 95, Number 21, May 2016investigated the role of immunonutrition, specifically in color-
ectal surgery. To the best of our knowledge, no studies have
investigated immunonutrition within an ERAS program.
METHODS
Patients treated at 6 Spanish hospitals (University Hospital
of Elche, University Hospital Lozano Blesa, Hospital of Torre-
vieja, Marina Alta Hospital, Hospital of Manacor, and Virgen
del Puerto Hospital) with a preoperative diagnosis of colorectal
cancer between January 2014 and March 2015 were included.
All participating hospitals have vast experience in ERAS10–12
and are part of the ERAS Spain.
Study Design
The SONVI study is a prospective multicenter randomized
single-blind trial with 2 parallel treatment groups receiving either
the study product (an immune-enhancing feed (IEF)-ATEM-
PEROproduced byVegenat or hypercaloric, high-protein supple-
ment (HHS)-SUPRESSI ofVegenat) for 7 days prior to colorectal
resection and for 5 days postoperatively. The patients were
randomized using http://www.randomization.com.
Feeding Regimens
Patients who completed a staging workup and were
deemed suitable candidates for colorectal resection were
randomized to either the HHS group or IEF group. The contents
of each feed are listed in Table 1.
The patients were asked to consume 2 cartons (400mL) of
their assigned feed per day for 7 days prior to surgery and to
daily record the volume consumed in a dedicated ‘‘compliance
diary.’’ This dietary supplement was consumed in addition to
normal food intake. No patient received total parenteral nutri-
tion during the preoperative period of the trial. Postoperatively,
the patients were asked to consume 2 cartons (400mL) of either
feed each day for 5 days.
INCLUSION AND EXCLUSION CRITERIA
Inclusion Criteria
All patients were required to be at least 18 years of age, to
be scheduled for surgery for colorectal cancer, to be normo-
nourished and to provide written consent.
Exclusion Criteria
All patients who did not meet the inclusion criteria were
excluded. Other exclusion criteria included the need for emer-
gency surgery, an American Society of Anesthesiologists (ASA)
physical status IV, renal failure definedvia hemodialysis, patients
on immunomodulatory or nutritional supplements, hypersensi-
tivity to arginine, omega-3 fatty acids, or nucleotides, the inability
to consume oral nutrition (dysphagia, esophageal stricture, and
pyloric stenosis), psychiatric disorders, HIV, pregnancy, bowel
obstruction, and uncontrolled infection.
ERAS Protocol
The ERAS interventions used were based on previously
published protocols (10–12), which required that, during the
preoperative period, the patients be given advice and that they
receive intravenous iron supplementation in cases of preopera-
Moya et altive anemia and no preparation of the colon (diet low in fiber
and enemas before surgery). In all cases, all patients were
admitted to surgery day before or the same day. It also required
2 | www.md-journal.comthat the patients receive 4 carbohydrate-rich drinks (800mL) 1
day prior to surgery and 2 additional drinks (400mL each) on
the morning of surgery. During surgery, goal-directed fluids
were administered using esophageal Doppler monitoring,
hypothermia and drainages were avoided, and epidural anaes-
thesia used. After surgery, nasogastric tubes were not used;
rather, early mobilization was practiced, opioid-free pain con-
trol and prophylactic medication for nausea and vomiting used
and oral fluids were administered early.
The patients were discharged following the criteria in
ERAS. All patients were followed for at least 3 months. An
online database was prepared for the collection of data from the
various centers.
Protocol for the Prevention of Surgical Site
Vitamin C, mg 33 11
Choline, mg 55 55Infection
All patients were treated according to this protocol and
included an antiseptic shower with chlohexidine soap the same
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
day of the intervention, preoperative preparation of the skin
with chlohexidine/alcohol solution, intravenous surgical anti-
microbial prophylaxis (metronidazole and tobramycin) admi-
nistered 30minutes before incision, perioperative glucose levels
<200mg/dL, glove change every 90minutes, perioperative
maintenance of patient normothermia, and no bowel prep-
aration. For extraction of the surgical specimen it was used a
self-retractor for laparotomy (Alexis Wound Retractor; Applied
Medical, Rancho Santa Margarita, CA or 3M Steri-Drape
Wound Edge Protector, 3M, Minnesota). The incisions were
closed using buried triclosan-coated polydioxanone antimicro-
bial sutures (PDS Plus Antibacterial Suture; Ethicon Inc, Som-
erville, NJ); and irrigated with chorexidine solution. The
incision were coated with cyanoacrylate tissue adhesive (Der-
mabond; Ethicon Inc, Somerville, NJ).
Outcome Measures
Patient baseline characteristics at the time of surgery (age,
sex, ASA status, and major comorbidities) were obtained from
each patient. ERAS compliance was determined and recorded in
the database. Compliance with all interventions was combined
and expressed as the percentage of patients who received the
correct intervention and documentation.
The 30-day postoperative complications were recorded.
Complications were defined as any deviation from the normal
postoperative course and divided into minor and major com-
plications. Minor complications included minor risk events,
such as wounds infection opened at the bedside, urinary tract
infection, or postoperative ileus (Clavien-Dindo I–II).13 Major
complications included potentially life-threatening compli-
cation and those with a need of surgical, endoscopic, or
radiological intervention, such as anastomotic leak, abdominal
abscess, and pneumonia (Clavien-Dindo III–IV).13 Surgical site
infection was defined according to the Centers for Disease
Control and Prevention classification of surgical site infection
and divided into superficial and deep incisional (spontaneous
drainage of purulent material from the wound or from the
surgeon’s deliberate revision and positive culture of drained
serous fluid) or organ/space infection. LOS, rates, and causes of
readmissions were also documented.
Analytical (hemoglobin, leukocytes, lymphocytes, procal-
citonin, and C-reactive protein) and nutritional (total protein,
albumin, prealbumin, transferrin, and zinc) variables were
determined before nutritional supplementation, on the day of
surgery and on the third day postoperatively.
Ethics
The study was presented to each Hospital Ethical Board
and accepted as an interventional multicenter randomized
study. The research was conducted in accordance with the
Helsinki Declaration and local legislation. The patients gave
informed consent to participate in the study. This study has been
registered in the NCT register as NCT02393976.
Sample Size Calculation
The hypothesis of this trial was that immunonutrition
would reduce the overall postoperative 30-day morbidity rate.
The sample size calculation was based on the detection of
significant differences in the primary endpoint parameter of
the trial. We assumed a postoperative infectious complication
Medicine  Volume 95, Number 21, May 2016rate of 30% in the HHS group according to several complication
rates after colorectal surgery.14–21 With an expected compli-
cation rate of 15% in the IEF group, the trial sample size
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.necessary for power of 80% and a 1-sided significance level
of 0.05 was calculated to be 119 patients per group. An assumed
10% dropout rate in this trial (due to noncompliance, intoler-
ance, etc.) increased the sample size to 132 patients per group.
Therefore, at least 264 patients had to be included in the trial.
Statistical Analyses
Statistical analyses of any differences between the 2
groups were performed using SPSS version 22 (SPSS Inc,
Chicago, IL). The data were presented as the means standard
standard deviations or as medians and interquartile ranges
where appropriate. For dichotomous outcomes, the treatment
groups were compared using the x2 test. Mann–Whitney U and
Kruskal–Wallis tests were used for continuous, non-normally
distributed outcomes. For continuous, normally distributed
data, ANOVA was used.
RESULTS
Patients
Figure 1 shows the CONSORT flowchart for the study. A
total of 264 patients were randomized, 7 of whom did not
receive the intervention and 13 opted not to participate after the
study started. Thus, 244 of the patients who were recruited to the
trial over an 18-month period (HHS, n¼ 122; IEF, n¼ 122)
completed the 7-day preoperative phase of the study.
The median age of the patients was 69 years (41–89);
46.3% were women (113 patients). The patients’ ASA physical
status classifications were distributed as follows: I, 14.8% (36);
II, 63.9% (156); and III, 21.3% (52).
At baseline, the 2 groups were comparable for age, sex,
surgical risk, comorbidity (Table 2), and analytical and nutri-
tional parameters (Table 3).
Results After 7 Days of Preoperative Nutritional
Supplementation
Patient Enteral Nutritional Supplementation Compliance
and Tolerance
All patients completed the preoperative nutritional treat-
ment with a consumption of 400 mL per day. There were no
differences between groups in the volume of preoperative
drinks consumed. Preoperatively, the nutritional supplement
drinks did not reduce the patients’ percentage of normal
diet intake.
Nutritional Laboratory Parameters
The results at baseline and after 7 days of preoperative
feeding are shown in Table 3. At the time of recruitment, there
were no significant differences between the 2 groups in serum
protein, albumin, prealbumin, transferring, and zinc; this was
also true after the nutritional treatment. However, levels of
serum proteins, albumin, and zinc after the nutritional inter-
vention were significantly higher in both groups compared with
the initial determination. No significant changes in the levels of
transferrin were observed after 7 days of preoperative feeding in
either group (Table 3).
Analytical Parameters
The results at baseline and after 7 days of preoperative
Eras and Immunonutrition in Colorectal Surgeryfeeding are shown in Table 3. At recruitment, there were no
significant differences between the 2 groups in hemoglobin
levels, leukocytes, lymphocytes, procalcitonin, or C-reactive
www.md-journal.com | 3
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However, the levels of hemoglobin (ERAS includes intravenous
iron supplementation in cases of preoperative anemia) and
lymphocytes after the nutritional intervention were significantly
higher in both groups. No significant changes in the levels of
leukocytes, procalcitonin, or C-reactive protein were observed
after 7 days of preoperative feeding in either group (Table 3).
Surgery, Postoperative Treatment, and
Postoperative Nutritional Supplementation
Of the patients, 74.6% (182) underwent laparoscopic
surgery; 25.4% (62) underwent open surgery. Some 8.8% of
the laparoscopically intervened patients required conversion to
laparotomy (16). Sigmoidectomy and right hemicolectomy
made up the majority of procedures performed (54.1%). The
mean duration of surgery was 161.72minutes (60–380). The
FIGURE 1. Flow diagram for the trial.median length of time spent in the recovery room was 208min-
utes (60–540). There were no significant differences between
the 2 groups in terms of the operative time or estimated
4 | www.md-journal.comintraoperative blood loss (121,210 mL 12,706 vs. 109,467
mL 11,804, P¼ 0,321). Table 2 shows the surgical techniques
used and the surgical procedures followed.
Main Features of the Protocol and Their
Compliance Rates
Table 4 shows the compliance rates for the main features
outlined in the ERAS protocol by groups. We did not find
significant differences between the groups. The overall com-
pliance to the protocol was approximately 80% but varied
widely in its various components without differences between
the groups.
Patient Enteral Nutritional Supplementation
Compliance and ToleranceAfter surgery, supplement intake averaged
205 12.61mL on the operative day. There were no differences
between groups in the volume of postoperative drinks
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Characteristics and Surgical Procedures of the 2 Groups
Patients Characteristics
Without Perioperative Immunonutrition With Perioperative Immunonutrition
P ValueN¼ 122 N¼ 122
Age, y 68 (41–89) 70 (42–88) 0.199
Sex 0.369
Female 53 (43.4%) 60 (49.2%)
Male 69 (56.6%) 62 (50.8%)
BMI, kg/m2
26.64 6.13 27.05 7.35 0.635
Surgical risk: ASA 0.934
ASA I 17 (13.9%) 19 (15.6%)
ASA II 79 (64.8%) 77 (63.1%)
ASA III 26 (21.3%) 26 (21.3%)
Morbidity
Diabetes 22 (18.0%) 17 (13.9%) 0.382
Hypertension 32 (26.2%) 40 (32.8%) 0.261
Heart disease 12 (9.8%) 7 (5.7%) 0.232
Respiratory disease 11 (9.0%) 9 (7.4%) 0.641
TNM
Carcinoma in situ 6 (4.9%) 8 (6.6%) 0.857
Stage I 38 (31.1%) 32 (26.2%)
Stage II 43 (35.2%) 41 (33.65)
Stage III 22 (18.0) 26 (21.3%)
Stage IV 13 (10.7%) 15 (12.3%)
Surgical technique 0.796
Laparoscopy 90 (73.8%) 92 (75.4%)
Conventional 32 (26.2%) 30 (24.6%)
Surgical procedure 0.640
Right hemicolectomy 35 (28.7%) 37 (30.3%)
Extended right hemicolectomy 3 (2.5%) 9 (7.4%)
Transverse resection 2 (1.6%) 0 (0%)
Left hemicolectomy 7 (5.7%) 5 (4.1%)
Sigmoidectomy 30 (24.6%) 30 (24.6%)
High anterior resection 16 (13.1%) 13 (10.7%)
Low anterior resection 23 (18.9%) 22 (18.0%)
Subtotal colectomy 3 (2.5%) 4 (3.3%)
Abdominoperineal amputation 3 (2.5%) 2 (1.6%)
Anastomosis technique 0.605
Manual 18 (15.8%) 22 (18.3%)
Mechanic 96 (84.2%) 98 (81.7%)
axim
Medicine  Volume 95, Number 21, May 2016 Eras and Immunonutrition in Colorectal Surgeryconsumed (211 12.68mL for HHS and 198 12.56mL for
IEF; P¼ 0.389).
Postoperative nutritional supplement tolerance was deter-
mined to be good in 154 patients (79 patients for IEF and 75
patients for HHS) and poor in 67 patients (34 for IEF and 33 for
HHS). No supplement was ingested by 23 patients (9 and 14
patients for IEF and HHS, respectively). There were no sig-
nificant differences between groups (P¼ 0.940).
Among the patients with poor tolerance, 9 in each group had
nausea (27.3% in HHS and 26.5% in IEF), 31 (36.4 and 55.9%,
respectively) had heaviness, 11 had heartburn (24.2 and 8.8%,
respectively), and 7 had vomiting (12.1%and8.8%, respectively).
There were no statistically significant differences (P¼ 0.263).
Some 62.3% (76) forHHS and 65.6% (80) for IEF complied
Quantitative variables are expressed as medians plus minimum and m
percentages.with the postoperative nutritional protocol (P¼ 0.594). Post-
operatively, the nutritional supplements did not reduce the per-
centage of normal diet consumed by the patients.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Postoperative Hospital Stay and Readmission
Rate
The median length of the postoperative hospital stay was
5 days (3–52 days, 5 days for HHS (3–52) and 5 days for IEF
(3–20)) with no difference between groups (P¼ 1.000). Of the
patients, 3.27% (8 patients, 4 in each group) were readmitted
following discharge for medical or surgical reasons without
statistically significant between-group differences. Two
patients presented with febrile syndrome, 3 with diarrhea, 1
with an abdominal wall abscess, 1 with a late anastomotic leak,
and 1 with vomiting.
Postoperative Morbidity/Mortality
um values; qualitative variables are expressed as absolute numbers andTable 5 summarizes the complications encountered.
Approximately 71% of the patients had an uneventful post-
operative course without complications. As shown in the table,
www.md-journal.com | 5
TABLE 3. Variations of Nutritional and Analytical Parameters
Without Perioperative Immunonutrition With Perioperative ImmunonutritionTime
Point N¼ 122 N¼ 122
No IMN Vs.
IMN P Value
Nutritional parameters
Serum protein Day 7 6.244 0.8460 6.207 0.8405 P¼ 0.863
Day 0 6.609 0.9011 6.543 0.9240 P¼ 0.950
Day 7 vs. Day 0 PU 0.000 PU 0.000
Day þ3 5.417 0.7858 5.378 0.8497 P¼ 0.747
Day 0 vs. Day þ3 PU 0.000y PU 0.000y
Albumin Day 7 3.637 0.5925 3.701 0.5596 P¼ 0.492
Day 0 3.804 0.6887 3.849 0.7397 P¼ 0.631
Day 7 vs. Day 0 PU 0.044 PU 0.036
Day þ3 3.038 0.6306 3.015 0.4871 P¼ 0.890
Day 0 vs. Day þ3 PU 0.000y PU 0.000y
Prealbumin Day 7 29.846 13.5532 29.416 9.1751 P¼ 0.398
Day 0 30.114 12.8996 30.707 10.5840 P¼ 0.789
Day 7 vs. Day 0 P¼ 0.691 P¼ 0.362
Day þ3 25.084 15.7436 25.986 11.3663 P¼ 0.993
Day 0 vs. Day þ3 PU 0.000y PU 0.000y
Transferrin Day 7 308.02 70.576 307.07 76.087 P¼ 0.439
Day 0 309.89 67.338 308.17 66.001 P¼ 0.300
Day 7 vs. Day 0 P¼ 0.720 P¼ 0.854
Day þ3 275.83 90.405 287.77 95.956 P¼ 0.691
Day 0 vs. Day þ3 PU 0.007y PU 0.000y
Zinc Day 7 69.129 16.2633 71.745 16.6041 P¼ 0.420
Day 0 74.540 14.5903 77.178 15.2985 P¼ 0.094
Day 7 vs. Day 0 PU 0.000 PU 0.003
Day þ3 64.225 22.9846 69.236 15.1272 P¼ 0.348
Day 0 vs. Day þ3 PU 0.000y PU 0.002y
Analytical Parameters
Hemoglobin Day 7 12.186 1.6940 12.176 1.5096 P¼ 0.965
Day 0 12.734 2.0344 12.744 1.6448 P¼ 0.699
Day 7 vs. Day 0 PU 0.000 PU 0.000
Day þ3 10.965 1.5866 10.870 1.4809 P¼ 0.638
Day 0 vs. Day þ3 PU 0.000y PU 0.000y
Leukocytes Day 7 8.0380 4.19215 8.0945 3.48117 P¼ 0.917
Day 0 8.2754 5.88325 8.1160 3.15727 P¼ 0.614
Day 7 vs. Day 0 P¼ 0.429 P¼ 0.922
Day þ3 8.8953 4.10177 8.970 4.04927 P¼ 0.890
Day 0 vs. Day þ3 PU 0.023y PU 0.000y
Lymphocytes Day 7 1.8813 1.11380 1.8693 3.46098 P¼ 0.990
Day 0 2.1412 1.02489 2.6785 5.97097 P¼ 0.443
Day 7 vs. Day 0 PU 0.002 PU 0.024
Day þ3 1.3698 0.80401 1.6903 1.10967 PU 0.023
Day 0 vs. Day þ3 PU 0.0012y PU 0.000y
Procalcitonin Day 7 0.1944 0.24598 0.1976 0.24542 P¼ 0.516
Day 0 0.1765 0.21505 0.1767 0.21475 P¼ 0.904
Day 7 vs. Day 0 P¼ 0.398 P¼ 0.449
Day þ3 1.4461 4.65345 1.1818 1.78219 P¼ 0.890
Day 0 vs. Day þ3 PU 0.043y PU 0.000y
C-reactive protein Day 7 7.3823 9.45163 7.2911 18.23828 P¼ 0.993
Day 0 6.7446 12.49258 6.2431 13.44207 P¼ 0.752
Day 7 vs. Day 0 P¼ 0.625 P¼ 0.499
Day þ3 61.1248 94.66588 64.0397 82.73042 P¼ 0.774
Day 0 vs. Day þ3 PU 0.000y PU 0.000y
Data are expressed as meanSEM.
IMN¼ immunonutrition.
Paired t test before and after nutritional intervention preoperative.
yPaired t test Day 0 vs. Day þ3.
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TABLE 4. Compliance With ERAS Protocol of the 2 Groups
Compliance With ERAS Protocol
Without Perioperative
Immunonutrition
With Perioperative
Immunonutrition
P ValueN¼ 122 N¼ 122
Preoperative
Perioperative information 122 (100%) 122 (100%) P¼ 1.000
No colon preparation protocol 106 (86.9%)

109 (89.3%)

P¼ 0.553
Carbohydrate-rich drinks on day before surgery 78 (63.9%) 79 (64.8%) P¼ 0.894
Carbohydrate-rich drinks before surgery 78 (63.9%) 78 (63.9%) P¼ 1.000
Surgery
Goal directed fluids 87 (71.3%) 85 (69.7%) P¼ 0.779
No hypothermia 114 (93.4%) 109 (90.1%) P¼ 0.341
No drainage 81 (66.4%) 88 (72.1%) P¼ 0.634
Epidural anaesthesia 90 (73.8%) 96 (78.7%) P¼ 0.367
Postoperative
No nasogastric tube 117 (95.9%) 114 (93.4%) P¼ 0.392
Early mobilisation 89 (73.0%) 99 (81.1%) P¼ 0.128
Early taking of fluids by mouth 100 (82%) 108 (88.5%) P¼ 0.149
Opioid-free pain control 88 (72.1%) 85 (69.7%) P¼ 0.672
Prophylactic medication for nausea and vomiting 105 (86.1%) 99 (81.1%) P¼ 0.299
Medicine  Volume 95, Number 21, May 2016 Eras and Immunonutrition in Colorectal Surgeryglobally, the patients who received immunonutrition presented
with fewer complications (23% vs. 35.20%, P¼ 0.035).
Themost common complicationswere surgical (19.25%; 47
patients) followed by infectious complications (17.25%; 42). The
most common surgical complications were paralytic ileus
(10.65%; 26) and anastomosis leakage (6.55%; 16) (Table 6).
Finally, themost common infectious complicationswere surgical
site infection (superficial and deep incisional site infection (11%;

No diet low in fiber or enemas given preoperatively.27) and organ/space infection (1.6%; 3)), urinary tract infection
(0.8%; 2), and respiratory infection (2%; 5). Nineteen patients
(8.8%) required repeat surgery. Causes included anastomotic
TABLE 5. Complications
Without Periopera
Immunonutritio
Outcome Variable N¼ 122
Percentage with any complications

35.20%
Percentage with any surgical complications

21.30%
Anastomotic leak 8.20%
Ileus 13.10%
Others 0.80%
Percentage with any infectious complications

23.80%
Surgical site infection 17.2%
Superficial and Deep incisional 16.4%
Organ/Space 2.40%
Pneumonia 3.30%
Urinary tract infection 0.80%
Venous catheter infection 7.40%
Mortality 0%
Reoperation rate 9%
RR¼ relative risk with 95% confidence interval in ().
Note that a patient may experience more than one complication.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.leakage (16), hemoperitoneum (2), and internal hernia (1). No
patients died during the hospital stay or following discharge.
Table 5 shows the differences between the groups. There
were fewer complications in IEF than HHS, primarily due to a
significant decrease in infectious complications (23.8% vs.
10.7%, P¼ 0.0007). Among the infectious complications, sur-
gical site infection was significantly different between groups
(17.2% vs. 5.7%, P¼ 0.0005). After excluding patients with
anastomotic dehiscence, surgical site infection remains higher
in HHS (12.7% vs. 4.4%, P¼ 0.039). Other infectious compli-
cations were lower for IEF but without statistically significant
tive
n
With Perioperative
Immunonutrition
N¼ 122 RR (95% CI) P Value
23.00% 0.547 (0.312–0.960) 0.035
17.20% 0.768 (0.405–1.455) 0.417
4.90% 0.579 (0.204–1.647) 0.301
8.20% 0.592 (0.257–1.361) 0.213
3.30% 4.102 (0.452–37.238) 0.175
10.70% 0.382 (0.188–0.778) 0.007
5.70% 0.293 (0.119–0.717) 0.005
5.70% 0.310 (0.126–0.764) 0.008
0.80% 0.328 (0.034–3.196) 0.313
1.60% 0.492 (0.088–2.736) 0.408
0.80% 1.000 (0.062–16.171) 1
3.30% 0.426 (0.127–1.421) 0.154
0%
6.60% 0.708 (0.275–1.826) 0.474
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TABLE 6. Characteristics and Surgical Procedures in Patients With Anastomotic Leaks
Without Perioperative
Immunonutrition
With Perioperative
Immunonutrition
Patients With Anastomotic Leak N¼ 10 N¼ 6 P Value
Age, y 69 (55–81) 69 (51–80) 0.894
Sex 0.551
Female 2 (20%) 2 (33.3%)
Male 8 (80%) 4 (66.7%)
BMI. kg/m2 27.92 8.11 26.22 6.24 0.668
Surgical risk: ASA 0.424
ASA I 0 0
ASA II 7 (70%) 3 (50%)
ASA III 3 (30%) 3 (50%)
Morbidity
Diabetes 1 (10%) 0 0.424
Hypertension 3 (30%) 2 (33.3%) 0.889
Heart disease 5 (50%) 1 (16.7%) 0.182
Respiratory disease 1 (10%) 0 0.424
Surgical technique 0.869
Laparoscopy 8 (80%) 5 (83.3%)
Conventional 2 (20%) 1 (16.7%)
Surgical procedure 0.813
Right hemicolectomy 4 (40%) 3 (50%)
Extended right hemicolectomy 0 0
Transverse resection 0 0
Left hemicolectomy 2 (20%) 0
Sigmoidectomy 1 (10%) 1 (16.7%)
High anterior resection 1 (10%) 1 (16.7%)
Low anterior resection 2 (20%) 1 (16.7%)
Subtotal colectomy 0 0
Abdominoperineal amputation 0 0
Anastomosis technique 0.696
Manual 1 (10%) 1 (16.7%)
Mechanic 9 (90%) 5 (83.3%)
Neoadjuvant theraphy 3 (30%) 2 (33.3%) 0.869
Quantitative variables are expressed as medians plus minimum and maximum values; qualitative variables are expressed as absolute numbers and
percentages.
Moya et al Medicine  Volume 95, Number 21, May 2016differences. When the analysis according to the approach path is
performed, we observe that, apart from this, a decrease in
infectious complications occurs (P¼ 0.044 for laparoscopic
surgery and P¼ 0.049 for conventional surgery).
Complications according to the Clavien-Dindo13 classifi-
cation are shown in Table 7. To further analyze complications,
we divided them into minor (Clavien-Dindo I–II) and major
(Clavien-Dindo III–IV) and observed a minor complication
incidence of 19.3% (for IEF and HHS, 25.4% vs. 13.1%,
respectively, with statistically significant differences
(P¼ 0.048)) and major complication incidence of 9.8%
(9.8% vs. 9.8%).
Nutritional Laboratory Parameters
For both groups, the postoperative serum protein, albumin,
prealbumin, transferring, and zinc levels were substantially
decreased compared with the preoperative levels. The post-
operative serum levels show a similar drop between groups
(Table 3).
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In both groups, postoperative serum hemoglobin levels
were substantially decreased compared with preoperative levels
(P¼ 0.000). Likewise, we observed an increase in white blood
cell count, C-reactive protein, and procalcitonin and decreased
lymphocyte count compared with their preoperative values. All
of these postoperative changes were similar between the
2 groups, with the exception of lymphocyte levels in the plasma.
This decrease was greater in the HHS patients, that is, IEF
patients had higher levels of lymphocytes on the third post-
operative day (P¼ 0.023). Postoperative levels are shown in
Table 3.
DISCUSSION
This trial showed that the combination of ERAS care and
immunonutrient supplements reduces postoperative compli-
cations. Patients receiving immunonutrients preoperatively
and postoperatively had fewer complications (primarily infec-
tious) than those who received standard supplements. Notably,
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 7. Complications According to Clavien–Dindo Classification
Clavien-Dindo Classification
Without Perioperative Immunonutrition With Perioperative Immunonutrition P Value
N¼ 122 N¼ 122 0.144
No complication 64.80% 77.00%
Clavien-Dindo I 12.30% 5.70%
Clavien-Dindo II 13.10% 7.40%
Medicine  Volume 95, Number 21, May 2016 Eras and Immunonutrition in Colorectal Surgerythis study is the first to demonstrate the advantages of using
immunonutrients in an ERAS protocol. Guidelines22 currently
recommend the use of immunonutrients within these protocols;
however, these recommendations have been based on scant
scientific evidence. This study provides stronger evidence for
this recommendation.
The first issue to be addressed when analyzing the results
of our study is the use of nutritional supplements in well-
nourished patients. The role of these supplements in malnour-
ished patients is obvious; however, the role of nutritional
supplements in well-nourished patients who are undergoing
colorectal surgery is currently debated. Traditionally, supple-
mentation would not be recommended for these patients; how-
ever, its use in maintaining or even improving the nutritional
status of patients before surgery has spread. As our results show,
supplements led to significant improvements in nutritional
values (in both the IEF and HHS groups) despite being con-
sumed for only 7 days preoperatively. Levels of serum proteins,
albumin, and zinc after nutritional intervention increased even
though we only include normo-nourished patients. It is therefore
possible to improve the nutritional status of these patients with
short-term preoperative supplementation, regardless of whether
the products contain immunonutrients. Our results are consist-
ent with a recent meta-analysis23 published by Hegazi et al,
which recommended the use of preoperative nutritional supple-
ments to prepare surgical patients regardless of their nutritional
status.
However, surgery is a stressor on the patient and induces
changes in the activity of both innate and adaptive immunity.24
Immune system responses after surgery can be inappropriate in
some cases (e.g., systemic inflammatory response syndrome).
To modulate this response, patients have recently received
nutritional formulas containing certain immunonutrients, prim-
arily arginine, glutamine, omega-3 fatty acids, and nucleotides.
However, scientific evidence regarding the effectiveness of this
supplementation is limited. Our results improve our knowledge
of the benefits of using these substances in surgical patients.
In that same meta-analysis, no significant differences were
observed between preoperative immunonutrition and standard
nutrition in their effects on postoperative clinical outcomes for
any type of surgery,23 while our results indicate otherwise.
Inmunonutrition supplementation reduces global complications
and infectious complications and may even, as some studies
indicate, reduce anastomotic leaks.25–27 Perioperative admin-
istration was associated with a statistically significant reduction
in anastomotic dehiscence, whereas a reduction in noninfective
complications was demonstrated with postoperative adminis-
tration in another meta-analysis.28 Our results are consistent
Clavien-Dindo III 3.30%
Clavien-Dindo IV 6.60%with these meta-analyses; however, despite observing a lower
incidence of anastomotic leaks, these results were not statisti-
cally significant. Notably, infectious complications were clearly
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.reduced when the diet was supplemented with immunonutri-
ents. However, due to the improvements in nutritional analytical
values in both groups and because the best results in terms of
morbidity and mortality were obtained in the immunonutrition
group, we recommend that immunonutrient supplementation be
provided both preoperatively and postoperatively.
Our study is one of few that focus only on patients
undergoing treatment for colorectal cancer. Most existing stu-
dies include a variety of gastrointestinal surgeries. Additionally,
the published results are contradictory in some cases.
For example, Braga et al29 demonstrated that perioperative
administration of enteral supplements enriched with arginine,
RNA, and omega-3 fatty acids decreases the rate of postopera-
tive infections. The same group, which is based at the Univer-
sity of San Rafael in Milan, performed another interesting study
comparing 4 groups: 1 group received arginine supplements and
omega-3 fatty acids for 5 days preoperatively; another group,
pre- and postoperative immunonutrient supplements; a third
group, standard isoenergetic and isonitrogenous supplements;
and a fourth group, no supplements. In this study, immunonu-
trition supplementation improved immune response and
increased intestinal microperfusion and oxygenation. There
are additional benefits to the postoperative extension of immu-
nonutrition.30 Horie et al31 stated that preoperative immunonu-
trition can reduce the rate of surgical site infection.
However, not all published results find benefits of immu-
nonutrients in terms of postoperative infection. Helminen et al32
observed no benefit for routinely prescribed immunonutrition.
Sorensen et al33 (elective surgery for colorectal cancer) and
Finco et al34 (laparoscopic colorectal surgery) reached the
same conclusion.
Another important aspect of our study is the less marked
reduction in lymphocyte values experienced by the immunonu-
trition group postoperatively. As the only value with statisti-
cally significant differences in both groups, we can assume that
the existing difference in postoperative complications between
the groups may result from these values. In fact, it has recently
been reported that a shift toward Th2 dominance in the Th1/Th2
cytokines during the early postoperative period is directly
associated with infectious complications.35 Matsuda et al36
described a correction in the balance of Th1/Th2 cytokines
in patients with colorectal cancer who were undergoing surgery
and received an oral diet supplemented with arginine, omega-3
fatty acids, and ribonucleic acid. They concluded that this
balance correction may be an important determinant of the
clinical benefits of immunonutrients and of how immunonutri-
tion reduces postsurgical infections.
The degree of compliance with the items included in the
4.90%
4.90%ERAS program is an important factor in the reduction of
postoperative complications and the achievement of early
recovery of our patients. In our study, compliance was higher
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23. Hegazi RA, Hustead DS, Evans DC. Preoperative standardthan 80%. If we compare these results with those recently
published by The ERAS Compliance Group37 (overall com-
pliance of 76.6% for colon cancer and 75.0% for rectal cancer),
the compliance rates are very similar and much higher than
those published when we started these programs.10 It is there-
fore shown that compliance increases as the teams gain experi-
ence in these protocols.
Although ERAS reduces the risk of complications com-
pared with the traditional treatment scheme38 and each of the
steps outlined in ERAS is based on scientific evidence, it is
necessary to continue working on methods to reduce compli-
cations. Immunonutrition represents one of these potential
points of entry.
Our study has some limitations. First, the number of cases
was insufficient to make robust conclusions and the sample size
has been calculated to obtain a statistically significant differ-
ence for infectious complications. We suggest a study with
more participants to check if noninfectious complications also
decreased when inmunonutientes enriched supplements are
used. Second, not all patients could ingest all postoperative
supplements, although there were no differences in intake
between the 2 groups. Likewise, although similar in compo-
sition (except immunonutrients), there is a global difference of
approximately 100 kcal per day between the 2 nutritional
supplements, we do not believe that influence, as well as this
dietary supplement was consumed in addition to normal food
intake. Third, not being double-blind study could contribute to
some form of bias. On the other hand, our study was performed
at 6 reference centers in Spain with multidisciplinary teams who
were fully dedicated to colorectal surgery and had previous
experience in the implementation of ERAS programs. There-
fore, it may be difficult to reproduce our results in nonexper-
ienced groups. Finally, despite using 2 comparable groups, we
included various surgical procedures and 2 modalities (laparo-
scopic and conventional).
CONCLUSIONS
Based on the data from the present multicenter, random-
ized study, the implementation of ERAS protocols including
immunonutrient-enriched supplements reduces complications
in patients undergoing colorectal resection. However, further
studies are needed to understand how immunonutrients improve
the prognosis of patients with colorectal cancer and the potential
mechanisms involved in immunonutrient-enriched supplements
reduces the complications of patients undergoing colorectal
resection.
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